Final Report

305
YAMIN, YASSER ZZ, MAHMOUD FAHIM Specimen ID: 305555890
NATIONAL BLOOD & CANCER CTR DOB: 09-OCT-1998 Age: 25Y Sex: M Date Reported: 14-NOV-2023 19:45
KING ABDULLAH ROAD, EXIT 10 Date Collected: 12-OCT-2023 12:53
Ethnicity: Unknown
RIYADH, AR 12482 SAUDI ARABIA
Surgical #: S23-6246 Date Received: 02-NOV-2023
ACCT #: SA100 AP
Patient ID: 19605 Asia Arabia Time Zone
P:6612881144 Source: CECUM AND TERMINAL ILEUM
Clinical Information: Ileo-cecal
intussusception

LYMPHOMA IMMUNOHISTOCHEMICAL ANALYSIS

INTERPRETATION
CECUM AND TERMINAL ILEUM, HEMICOLECTOMY:
DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NON-GERMINAL CENTER CELL TYPE.

NOTE: SECTIONS OF THE CECAL MASS SHOW A DENSE DIFFUSE INFILTRATE OF ATYPICAL LYMPHOCYTES. THE
NEOPLASTIC LYMPHOCYTES APPEAR LARGE IN SIZE WITH A MODERATE AMOUNT OF EOSINOPHILIC CYTOPLASM,
OVOID NUCLEAR CONTOURS AND PROMINENT, OFTEN SINGLE, NUCLEOLI. SCATTERED EXTRACELLULAR APOPTOTIC
DEBRIS AND MITOTIC FIGURES ARE SEEN, BUT THERE ARE NO AREAS OF COAGULATIVE NECROSIS IDENTIFIED.
IMMUNOHISTOCHEMICAL STAINS SHOW THE NEOPLASTIC CELLS HAVE THE FOLLOWING PHENOTYPE: CD20+, CD5-,
BCL6+(DIM), CD10-, MUM1+, CD23+, CD30-, CD43+, BCL2+, CYCLIN D1-, AND SOX11-. THE PROLIFERATION INDEX OF THIS
NEOPLASM, AS ASSESSED WITH A STAIN FOR KI-67, IS APPROXIMATELY 80%. THERE IS A MILD INFILTRATE OF SMALL
REACTIVE T-CELLS (CD3+/CD5+).

THESE MORPHOLOGIC AND PHENOTYPIC FINDINGS ARE DIAGNOSTIC OF DLBCL, NON-GERMINAL CENTER CELL TYPE.
IN SITU HYBRIDIZATION FOR EBV MRNA (EBERISH) IS AND IHC FOR C-MYC ARE PENDING FOR FURTHER
CHARACTERIZATION. FISH STUDIES FOR MYC, BCL2 AND BCL6 WILL BE PERFORMED FOR EVALUATION OF DOUBLE HIT
LYMPHOMA AND ADDENDUM REPORT WILL FOLLOW.

RESULTS
Antibody Clone Description Results
BLOCK 1C
CD20 L26 Pan B-cell antigen B-cells positive
CD3 2GV6 Pan T-cell antigen, TCR-epsilon subunit Negative
CD5 SP19 Pan T-cells, B-cell subset, thymic carcinoma Negative
CD10 SP67 Follicle center B-cells, endometrial stromal & Negative
myoepithelial cells, CALLA
CD23 SP23 B-cell subset, CLL/SLL, follicular dendritic Positive, dim
meshwork
CD43 L60 T-cells, myeloid cells, B-cell subset Positive, dim
CD30 BerH2 Activation Antigen, Reed-Sternberg cells. Negative
Cyclin D1 SP4-R Cyclin D1/PRAD1, mantle cell lymphoma Negative
SOX-11 MRQ-58 Mantle Cell Lymphoma (MCL) biomarker Negative
BCL-2 124 B-cell subset, follicular lymphoma Positive (3+)
BCL-6 GI191E/A8 Follicle center B-cells Positive dim/focal
MUM-1 EP190 Late stage B-cells, plasma cells, activated T- Positive
cells, Reed-Sternberg cells
Ki-67 30-9 Proliferation marker Positive (80%)
c-MYC Y69 Anti-c-MYC To Follow
EBER ISH PROBE ISH, inform EBER probe for Epstein-Barr virus, To Follow
Ventana Medical Systems

Debbie Buzaid, M.D. BioReference Health, LLC
Hematopathologist, ex. 8398 481 Edward H. Ross Drive
This report was electronically signed. Elmwood Park, NJ 07407
+1 201-791-2600
Page 1 of 2
Tamera Paczos, M.D. Created: 14-NOV-2023 13:02
Laboratory Director
RR
 Final Report
305
YAMIN, YASSER ZZ, MAHMOUD FAHIM Specimen ID: 305555890
NATIONAL BLOOD & CANCER CTR DOB: 09-OCT-1998 Age: 25Y Sex: M Date Reported: 14-NOV-2023 19:45
KING ABDULLAH ROAD, EXIT 10 Date Collected: 12-OCT-2023 12:53
Ethnicity: Unknown
RIYADH, AR 12482 SAUDI ARABIA
Surgical #: S23-6246 Date Received: 02-NOV-2023
ACCT #: SA100 AP
Patient ID: 19605 Asia Arabia Time Zone
P:6612881144 Source: CECUM AND TERMINAL ILEUM
Clinical Information: Ileo-cecal
intussusception

LYMPHOMA IMMUNOHISTOCHEMICAL ANALYSIS

COMMENT
A positive control for each antibody has been reviewed and accepted.

These tests were developed and their performance characteristics determined by BioReference Health, LLC. They may not be cleared or approved by the U.S. Food and
Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded
as investigational or for research. This laboratory has been approved by CLIA 88, designated as a high-complexity laboratory and is qualified to perform these tests.

Page 2 of 2
Debbie Buzaid, M.D. BioReference Health, LLC Tamera Paczos, M.D. Created: 14-NOV-2023 13:02
Hematopathologist, ex. 8398 481 Edward H. Ross Drive Laboratory Director
This report was electronically signed. Elmwood Park, NJ 07407
+1 201-791-2600 RR